select Archives ⋆ cdsalta.gob.ar

GDPR Compliance: Who's Affected? (Checklist)

The General Data Protection Regulation (GDPR) governs the processing of personal data of individuals located within the European Economic Area (EEA). It also applies to organizations located outside the EEA if they offer goods or services to, or monitor the behavior of, individuals in the EEA. Consider a company based in the United States that sells products online to customers in France. This company would be subject to GDPR regulations regarding the French customers’ data. Similarly, a social media platform headquartered outside the EEA, but used by individuals within the EEA, falls under the jurisdiction of the GDPR.

This regulation offers significant protections to individuals, granting them greater control over their personal information. This includes rights to access, rectify, and erase their data, as well as the right to restrict processing and data portability. Enacted in 2016 and becoming enforceable in 2018, the GDPR aimed to unify data privacy laws across Europe and enhance individual rights in the digital age. Its implementation has significantly impacted how organizations worldwide handle personal data, driving greater accountability and transparency in data processing practices.

Who Owns Select Rx? Parent Company & More

Determining the ownership of a pharmacy benefit manager (PBM) like Select Rx is essential for understanding its role within the healthcare system. This involves identifying the parent company, subsidiaries, and any other relevant stakeholders. For example, understanding ownership can clarify whether the PBM is part of a larger insurance conglomerate or operates independently. This information is crucial for assessing potential conflicts of interest, pricing structures, and negotiating contracts.

Transparency in PBM ownership provides valuable insights for employers, patients, and healthcare providers. It can shed light on how drug formularies are developed, how rebates are negotiated, and how profits are distributed. This knowledge empowers stakeholders to make informed decisions about prescription drug coverage and cost management strategies. Historically, the complex ownership structures of PBMs have contributed to a lack of transparency in drug pricing, making this type of investigation all the more critical.